Imunon, Inc. Contract Liability (Deferred Revenue)
Imunon, Inc. (IMNN) had Contract Liability (Deferred Revenue) of $125.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-03-30
- 2022-09-30: Contract with Customer, Liability, Current $125.00K.
- 2022-06-30: Contract with Customer, Liability, Current $250.00K.
- 2022-03-31: Contract with Customer, Liability, Current $375.00K.
- 2021-12-31: Contract with Customer, Liability, Current $500.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-09-30 | $125.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $250.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $375.00K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $500.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $500.00K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $500.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $500.00K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $500.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $500.00K 10-Q · filed 2020-11-16 |
| 2020-06-30 | $500.00K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $500.00K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $500.00K 10-K · filed 2021-03-19 |
| 2019-09-30 | $500.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $500.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $500.00K 10-Q · filed 2019-05-15 |
| 2018-12-31 | $500.00K 10-K · filed 2020-03-25 |
| 2017-12-31 | $500.00K 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |